Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanhong Gu

Showing results (151-160 of 154) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 154 results.
The Lancet. Gastroenterology & Hepatology|December 4, 2025
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRAS<sup>G12C</sup> mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trialsJian Li, Zhenghang Wang, Jing Huang, et al.
Nature Medicine|January 6, 2025
Glecirasib in KRAS<sup>G12C</sup>-mutated nonsmall-cell lung cancer: a phase 2b trialYuankai Shi, Jian Fang, Ligang Xing, et al.
Cancer Biology & Medicine|May 24, 2019
Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical OncologyXuchao Zhang, Zhiyong Liang, Shengyue Wang, et al.
Journal of Hematology & Oncology|February 16, 2019
Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition)Jian Li, Ying Yuan, Fan Yang, et al.
Pageof 16

Showing results (151-160 of 154) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 154 results.
The Lancet. Gastroenterology & Hepatology|December 4, 2025
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRAS<sup>G12C</sup> mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trialsJian Li, Zhenghang Wang, Jing Huang, et al.
Nature Medicine|January 6, 2025
Glecirasib in KRAS<sup>G12C</sup>-mutated nonsmall-cell lung cancer: a phase 2b trialYuankai Shi, Jian Fang, Ligang Xing, et al.
Cancer Biology & Medicine|May 24, 2019
Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical OncologyXuchao Zhang, Zhiyong Liang, Shengyue Wang, et al.
Journal of Hematology & Oncology|February 16, 2019
Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition)Jian Li, Ying Yuan, Fan Yang, et al.
Pageof 16